Which treatment is done in patients with metastatic breast cancer who received a prior treatment with CDK4/6 inhibitors? A real-world experience in a single italian Institution

被引：0
|
作者：
Bravaccini, Sara
Balzi, William
Roncadori, Andrea
Virga, Alessandra
Ulivi, Paola
Martinelli, Giovanni
Maltoni, Roberta
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-05-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-05-07
引用
收藏
页数：3
相关论文
共 50 条
  • [1] CDK4/6 inhibitors in metastatic breast cancer: An Italian real-world experience
    Pantano, F.
    Scafetta, R.
    Curigliano, G.
    Criscitiello, C.
    Botticelli, A.
    Caputo, R.
    D'Auria, G.
    Garrone, O.
    Gori, S.
    Meattini, I.
    Minelli, M.
    Piras, M.
    Rossi, L.
    Stucci, L. S.
    Tagliaferri, B.
    Toss, A.
    Vernieri, C.
    Vici, P.
    Tonini, G.
    Santini, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S346 - S347
  • [2] Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania
    Miron, Andreea-Iuliana
    Anghel, Alexandra-Valentina
    Barnonschi, Andrei-Alexandru
    Mitre, Ruxandra
    Liscu, Horia-Dan
    Gainariu, Estera
    Patru, Raluca
    Coniac, Simona
    DIAGNOSTICS, 2023, 13 (11)
  • [3] Which are the clinicopathological characteristics useful to define the metastatic breast cancer patients that will respond to CDK4/6 inhibitors and hormone therapy? An Italian real-world experience
    Bravaccini, Sara
    Roncadori, Andrea
    Balzi, William
    Martinelli, Giovanni
    Montella, Maria Teresa
    Palleschi, Michela
    Maltoni, Roberta
    CANCER RESEARCH, 2023, 83 (07)
  • [4] CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer
    Ettl, Johannes
    Huober, Jens
    Lueftner, Diana
    Marme, Frederik
    Wuerstlein, Rachel
    BREAST CARE, 2017, 12 (02) : 118 - 120
  • [5] Real-World Experience with CDK4/6 Inhibitors for Metastatic HR +/HER2-Breast Cancer at a Single Cancer Center
    Kovacevic, M. Milovic
    Bobic, S.
    Karaferic, A.
    Pavlovic, L.
    Matovic, M.
    BREAST, 2023, 68 : S46 - S46
  • [6] Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer at a Single Cancer Center
    Knudsen, Erik S.
    Schultz, Emily
    Hamilton, Deanna
    Attwood, Kris
    Edge, Stephen
    O'Connor, Tracey
    Levine, Ellis
    Witkiewicz, Agnieszka K.
    ONCOLOGIST, 2022, 27 (08): : 646 - 654
  • [7] Real-world experience with CDK4/6 inhibitors for metastatic HR+/HER2-breast cancer at a single cancer center
    Milovic-Kovacevic, M.
    Bobic, S.
    Karaferic, A.
    Pavlovic, L.
    Matovic, M.
    Poparic-Bandjur, B.
    BREAST, 2023, 68 : S115 - S115
  • [8] The impact of CDK4/6 inhibitors on bone health: An Italian real-world experience
    Scafetta, R.
    Pantano, F.
    Donato, M.
    Fiore, C.
    Foderaro, S.
    Guarino, A.
    Gullotta, C.
    Sisca, L.
    Ricozzi, V.
    De Giorgi, U. F. F.
    De Lisi, D.
    Fabbri, M. A.
    Irelli, A.
    Portarena, I.
    Tiberi, E.
    Verrazzo, A.
    Villa, F.
    Tonini, G.
    Vincenzi, B.
    Santini, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S349 - S349
  • [9] Real-world comparison of the efficacy of three CDK4/6 inhibitors (CDK4/6i) in the first-line treatment of endocrine-sensitive advanced breast cancer (aBC): Single institution experience
    Plavetic, Natalija Dedic
    Cular, Katarina
    Gudelj, Dora
    Kaceljak, Kristina
    Krizic, Marija
    Popovic, Marina
    Bulimbasic, Stela
    Sirotkovic-Skerlev, Maja
    Bubanovic, Sanda
    Silovski, Tajana
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] CDK4/6 inhibitors and endocrine therapy in the treatment of metastatic breast cancer: A real-world and propensity score-adjusted comparison
    Coutinho-Almeida, Joao
    Silva, Ana Sofia
    Redondo, Patricia
    Rodrigues, Pedro Pereira
    Ferreira, Ana
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 40
12345